Medscape11d
From Eczema to Rare Lymphoma: Delayed Diagnosis in a Child
Despite multiple treatments for eczema and pityriasis alba, a child’s skin condition worsened until a biopsy revealed mycosis ...
Innate Pharma: Moving Into The Padcev Space
Innate Pharma continues its slow rollout of promising clinical candidates, with 2025 set for key milestones. Read more about ...
Government of Canada signs bilateral agreement with Nunavut for Drugs for Rare Diseases
Today, the Honourable Mark Holland, Canada's Minister of Health, and the Honourable John Main, Nunavut's Minister of Health, announced a bilateral agreement investing over $7.3 million over three ...
The Canadian Press on MSN3d
Nova Scotia NDP questions lack of pharmacare deal with Ottawa
HALIFAX — Nova Scotia still hasn’t signed on to the federal government’s pharmacare plan, and the province’s Opposition New ...
Mirage News11d
Canada, Nunavut Ink Rare Disease Drug Pact
In Canada, 1 in 12 people live with a rare disease, and for most people affected, the cost of treatment is unaffordable. Canadians deserve a health care system that provides timely access to quality ...
Newswire25d
Government of Canada signs pharmacare agreement with Manitoba to improve affordable access to medications
Poteligeo, for the treatment of mycosis fungoides or Sézary syndrome; Oxlumo, for the treatment of primary hyperoxaluria type 1; Epkinly, for relapsed or refractory diffuse large B-cell lymphoma ...
Armed robbery in Revesby24d
Manitoba, CA Reach Rare Disease Drug Deal
Yescarta is a drug used to treat several forms of relapsed or refractory B-cell lymphomas in adults: follicular lymphoma, large B-cell lymphoma (LBCL), diffuse large B-cell lymphoma (DLBCL), and ...